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Abstract
Background:  Amylin (islet amyloid polypeptide) is a hormone with suggested roles in the
regulation of glucose homeostasis, gastric motor and secretory function and gastroprotection. In
the gastric mucosa amylin is found co-localised with somatostatin in D-cells. The factors regulating
gastric amylin release are unknown. In this study we have investigated the regulation of amylin
release from gastric mucosal cells in primary culture. Rabbit fundic mucosal cells enriched for D-
cells by counterflow elutriation were cultured for 40 hours. Amylin and somatostatin release over
2 hours in response to agonists were assessed.
Results: Amylin release was significantly enhanced by activation of protein kinase C with phorbol-
12-myristate-13-acetate, adenylate cyclase with forskolin and elevation of intracellular calcium with
A23187. Cholecystokinin (CCK), epinephrine and glucagon-like peptide-1 (GLP-1) each stimulated
amylin release in a dose-dependent manner. Maximal CCK-stimulated release was greater than
either epinephrine or GLP-1, even when the effects of the latter two were enhanced by
isobutylmethylxanthine. Stimulated amylin release was significantly inhibited by carbachol (by 51–
59%) and octreotide (by 33–42%). Somatostatin release paralleled that of amylin.
Conclusions: The cultured D-cell model provides a means of studying amylin release. Amylin
secretion is stimulated by receptor-dependent and -independent activation of Ca2+/protein kinase
C and adenylate cyclase pathways. Inhibition involves activation of muscarinic receptors and auto-
regulation by somatostatin.
Background
Amylin (islet amyloid polypeptide) is a 37-amino acid
peptide predominantly expressed in the pancreatic Islets
of Langerhans [1,2]. Amylin has also been localised
throughout the gastrointestinal tract [3] and in the brain
[4]. Much recent work has focused on the physiology of
pancreatic amylin; the peptide appears to be co-stored
and co-secreted with insulin in pancreatic B-cells [5,6], a
smaller proportion is co-localised with somatostatin in
pancreatic D-cells [7].
Amylin is believed to function as a hormone regulating
glucose homeostasis. Amylin inhibits basal and insulin-
stimulated glycogen synthesis in rat skeletal muscle [8,9];
it inhibits insulin, somatostatin and glucagon secretion
from isolated pancreatic islets and intact perfused
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pancreas and it reduces post-prandial glucagon and insu-
lin secretion [10–12]. Amylin may also contribute to gly-
caemic control by slowing gastric emptying [13]. It
addition to these physiological roles, amylin is believed to
play significant role in the pathogenesis of diabetes melli-
tus. It is the major component of the amyloid deposits in
the islets of patients with non-insulin dependent diabetes
mellitus [1,2] and deficiency of amylin may contribute
the failure of glycaemic control typical of insulin-depend-
ent diabetes [14] and in animal studies amylin itself
appears to induce insulin resistance [15].
A variety of physiological effects on the gastrointestinal
tract have also been described. Parenteral administration
of amylin has an anorectant effect [13], in addition to sig-
nificantly reducing gastric emptying [16]. A protectant
action against reserpine-, and serotonin-induced gastrop-
athy has been described [17]. Intravenous amylin is a
potent inhibitor of basal, pentagastrin and 2-deoxy-D-glu-
cose stimulated gastric acid secretion in the rat [18] and
amylin reduced acid secretion in the isolated mouse stom-
ach preparation [19]. A stimulant effect on serum gastrin
has also been reported, although this may have been sec-
ondary to the inhibition of acid secretion [20]. In keeping
with these actions amylin-binding sites have been
detected in rat gastric fundic mucosa [21]. Within the gas-
trointestinal tract amylin appears to co-localise with other
gastrointestinal peptides. Using in situ hybridisation,
immunofluorescence and immunocytochemistry, Mulder
et al showed that amylin predominantly co-localised with
somatostatin in the D-cells of rat and mouse antral
mucosa and rat fundic mucosa [22]. A minority of amylin
co-localised to separate populations of gastrin-containing
cells in the antrum and PYY-containing cells in the fun-
dus. Studies in PDX-1 deficient mice (which fail to
develop G-cells) demonstrated no alteration in gastric
amylin expression, confirming predominant expression
of amylin within D-cells [23]. These data showing the
presence of amylin and amylin receptors, coupled with
the pharmacological effects, suggested that amylin might
have a paracrine and/or endocrine regulatory and patho-
physiological role in the gastric mucosa. However there
are no studies exploring the processes involved in gastric
amylin secretion. Such data are a prerequisite for further
understanding of gastric amylin physiology. Primary cul-
tures of gastric and intestinal endocrine cells have been
utilised to examine the physiological and pathophysio-
logical control of several gastrointestinal peptides includ-
ing gastrin, somatostatin, glucagon-like peptide-1 (GLP-
1) and cholecystokinin (CCK) [24–30]. The co-localisa-
tion of amylin with somatostatin makes the gastric fundic
D-cell preparation a useful model to examine the control
of amylin secretion at the cellular level.
In this study we have examined receptor-dependant and
receptor-independent regulation of amylin secretion from
cultured rabbit gastric fundic mucosal cells. Cholecystoki-
nin, glucagon-like peptide-1 and epinephrine stimulated
amylin release in a dose dependant manner and the mus-
carinic receptor agonist carbachol and somatostatin recep-
tor agonist octreotide inhibited amylin release.
Somatostatin and amylin release occurred in parallel.
Results
Receptor-independent stimulation of peptide release
To initially assess whether amylin release could be
detected from the cultures of rabbit fundic cells, potent
receptor-independent stimuli were used [26] The total cell
content (TCC) of amylin in the cultured cell preparation
(801 ± 151 fmol/well) was approximately 4 to 5-fold
lower than that of somatostatin (3 768 ± 1325 fmol/well).
Significant stimulation of amylin release occurred with
the active phorbol ester (phorbol-12-myristate-13-acetate,
PMA) which activates protein kinase C (PKC), activation
of adenylate cyclase with forskolin and elevation of intra-
cellular calcium with the ionophore A23187 (Figure 1).
The phorbol ester was the most potent stimulant, leading
to 8.5 fold increase in amylin release (basal release 2.14 ±
0.8% increasing to 18.5 ± 1.4% of TCC). Forskolin
increased release 3.3 fold (maximal release 7.2 ± 1.4% of
TCC) and A23187 by 1.8 fold (3.8 ± 0.5% TCC), these
were markedly less potent than PMA. There were no sig-
nificant differences between the patterns of somatostatin
and amylin release (Fig. 1).
Receptor-dependent stimulation
Previous studies have demonstrated that CCK is a potent
stimulant of somatostatin release [26]. This was con-
firmed here. CCK dose-dependently stimulated release of
amylin from the cultured cells (Figure 2). Maximal stimu-
lation, a 2.75 fold increase, 2.1 ± 0.7% basal release
increased to 5.9 ± 0.8% TCC, occurred with CCK 10 nM.
A similar dose response pattern was seen for CCK-stimu-
lated somatostatin release although maximal release was
relatively higher for somatostatin (4.4 fold, 1.1 ± 0.1% to
5.2 ± 0.7% TCC) than amylin (Figure 2).
Activation of adenylate cyclase-coupled receptors with
either epinephrine or glucagon-like peptide-1 led to a
dose-dependent small increase in both somatostatin
(maximal increase 1.44 and 1.35 fold respectively) and
amylin release (1.36 and 1.25 and fold respectively) (Fig-
ures 3 and 4).
The responses to epinephrine and GLP-1 were enhanced
by co-administration with the phosphodiesterase inhibi-
tor isobutylmethylxanthine (IBMX) (100 µM). Basal amy-
lin release was 2.0 ± 0.2% TCC and maximal IBMX-
enhanced release 3.2 ± 0.2% TCC with epinephrine at 100BMC Physiology 2003, 3 http://www.biomedcentral.com/1472-6793/3/13
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µM and 3.2 ± 0.3% TCC with GLP-1 at 10 nM. Basal soma-
tostatin release (1.1 ± 0.1% TCC) increased to 2.7 ± 0.1%
TCC with epinephrine + IBMX and 2.1 ± 0.4% TCC with
GLP-1 + IBMX. These were still significantly less than
CCK-stimulated release. There were no differences in the
pattern or ratio of somatostatin and amylin responses
(Figures 3 and 4).
Inhibitory regulation of amylin release
Treatment with the somatostatin analogue octreotide pro-
duced small but non-significant reductions in both basal
amylin (by 14%) and basal somatostatin (by 18%) secre-
tion (Figure 5). Carbachol had no obvious effect on either
basal amylin or somatostatin secretion (Figure 5). CCK-
stimulated amylin release was significantly inhibited by
octreotide (by 42%) and the muscarinic agonist carbachol
(by 51%). Similarly epinephrine (with IBMX)-stimulated
amylin release was inhibited by 33% by octreotide and
59% by carbachol (both P < 0.05). As shown in figure 6,
a similar pattern was seen with somatostatin release.
Discussion
This is the first study to examine the release of amylin
from gastric mucosa at the cellular level. Results demon-
strated that amylin was not only stored in gastric mucosal
cells but also that putative physiological agonists regu-
lated release of the peptide. Previous studies have local-
ised amylin to the stomach using Northern blotting
[31,32], immunocytochemistry [33], radioimmunoassay
[3] and in situ hybridisation [22] but the release of gastric
amylin has not been demonstrated previously.
The majority of gastric fundic amylin appears to be local-
ised with somatostatin within D-cells [22] Therefore we
have used the cultured rabbit D-cell model to investigate
the agents controlling cellular release of amylin and to
compare this to somatostatin secretion.
Receptor-independent stimulation of amylin (top) and soma- tostatin (bottom) from cultured D-cells Figure 1
Receptor-independent stimulation of amylin (top) and soma-
tostatin (bottom) from cultured D-cells. Cells were stimu-
lated with phorbol-12-myristate-13-acetate 100 nM (PMA), 
forskolin 10 µM (FSK) and A23187 1 µM for 2 hours. Results 
expressed as % of cell content of peptide released, mean ± 
SEM, ** P < 0.01 vs. control, * P < 0.05 vs. control.
CCK-stimulated amylin (top) and somatostatin (bottom)  release from cultured D-cells Figure 2
CCK-stimulated amylin (top) and somatostatin (bottom) 
release from cultured D-cells. Cultured mucosal cells were 
stimulated with CCK for 2 hours. Results expressed as % of 
cell content of peptide released, mean ± SEM, * P < 0.05 vs. 
control.BMC Physiology 2003, 3 http://www.biomedcentral.com/1472-6793/3/13
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Initial studies were performed with potent agents known
to directly activate peptide secretion from endocrine cells
in a receptor-independent manner [26] Phorbol esters
(such a PMA) directly activate protein kinase C in the
inner layer of the cell membrane; this in turn activates the
cellular processes required for exocytosis. PMA was a
potent stimulant of both somatostatin and amylin secre-
tion. The calcium ionophore A23187, which increases lev-
els of intracellular calcium ([Ca2+]i]) also stimulated
amylin release, although it was significantly less potent
than PMA. This is similar to the responses seen in human
antral [26] and canine fundic D-cells [30] where it is
believe the rise in [Ca2+]i is mainly facilitative rather than
directly stimulating secretion. Direct activation of ade-
nylate cyclase with forskolin also stimulated amylin
release. Therefore the initial studies demonstrated that
amylin release could be stimulated by activation of either
of the two main intracellular signalling pathways known
to enhance peptide secretion. Having determined that
these pathways were active, we explored which physiolog-
Effect of epinephrine on amylin (top) and somatostatin (bot- tom) release from cultured D-cells Figure 3
Effect of epinephrine on amylin (top) and somatostatin (bot-
tom) release from cultured D-cells. Cells were stimulated 
with increasing concentrations of epinephrine (EPI) in the 
presence or absence of isobutylmethylxanthine 100 µM 
(IBMX) for 2 hours. Results expressed as % of cell content of 
peptide released, mean ± SEM, * P < 0.05 vs. control.
Effect of glucagon-like peptide-1 on amylin (top) and somato- statin (bottom) release from cultured D-cells Figure 4
Effect of glucagon-like peptide-1 on amylin (top) and somato-
statin (bottom) release from cultured D-cells. Cells were 
stimulated with increasing concentrations of glucagon-like 
peptide-1 (GLP) in the presence or absence of isobutylmeth-
ylxanthine 100 µM (IBMX) for 2 hours. Results expressed as 
% of cell content of peptide released, mean ± SEM, * P < 0.05 
vs. control.
Effect of octreotide and carbachol on basal amylin and soma- tostatin release from cultured D-cells Figure 5
Effect of octreotide and carbachol on basal amylin and soma-
tostatin release from cultured D-cells. D-cells were stimu-
lated with either octreotide 10 nM (OCT) or carbachol 100 
µM (CBH) for 2 hours and release of amylin and somatosta-
tin assessed. Results expressed as % of cell content of pep-
tide released, mean ± SEM.BMC Physiology 2003, 3 http://www.biomedcentral.com/1472-6793/3/13
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ical agents could stimulate amylin secretion in a receptor-
dependent manner.
Cholecystokinin-8 produced a dose-dependent increase
in amylin and somatostatin secretion. CCK is known to be
a potent in vitro stimulant of somatostatin release from
antral and fundic D-cells [26,30,34]. A similar dose
response was seen for amylin, although the overall incre-
ment was slightly greater for somatostatin than amylin.
Further studies will be needed to determine whether this
represents a separate pool of somatostatin specifically
secreted following stimulation with CCK. Fundic D-cells
appear to express both the CCK-1 (CCKA) and CCK-2
(gastrin/CCKB) receptors [35]. Activation of these recep-
tors triggers the activation of phospholipase C, release of
diacylglerol and inositol 1,4,5-trisphosphate and subse-
quent elevation of [Ca2+]i and activation of PKC, leading
to peptide release [36]. These results are consistent with
the results for A23187 and PMA stimulation. Therefore it
appears that CCK may act as a physiological stimulant of
amylin release.
Epinephrine and GLP-1 produced small dose-dependent
increases in amylin and somatostatin secretion. This effect
could be enhanced by co-treatment with the phosphodi-
esterase inhibitor IBMX, which inhibits cAMP breakdown
and amplifies responses generated by adenylate cyclase
coupled receptors. However the responses were still signif-
icantly less that those seen with activation of the Ca2+/
PKC pathway by either CCK or PMA. Similar differences
in the sensitivities have been described in human antral
[26] and canine fundic [30] D-cells.
The predominant inhibitory influences described thus far
on fundic D-cells are muscarinic agonists [37,38] and
autoregulation by somatostatin itself [39,40]. The
responses reported here are in keeping with the data on
somatostatin release from canine fundic D-cells [30,37].
In contrast, muscarinic receptors are stimulatory to antral
D-cells [41], probably reflecting a specific difference in
function. The current study confirmed the inhibitory
actions of both the somatostatin-analogue octreotide and
muscarinic agonist carbachol against somatostatin
release. A similar inhibition of stimulated amylin release
was seen. This suggests that in vivo inhibition of amylin
release involves parasympathetic input and autocrine reg-
ulation by somatostatin.
Under all conditions studied somatostatin and amylin
were secreted in parallel, as may be expected if they are co-
stored in secretory granules. Insulin and amylin are co-
secreted from pancreatic β-cells, secretion normally occurs
in parallel [42–44] but differential secretion has been
reported in experiment models of diabetes mellitus
[45,46]. Further studies will be needed to further define
the relationship between the secretion and actions of gas-
tric amylin and somatostatin. In isolated pancreatic islets
the two peptides appear to have a co-operative role in reg-
ulating peptide secretion: combined imunoneutralisation
of amylin and somatostatin resulted in greater enhance-
ment of insulin and glucagon secretion than neutralisa-
tion of either alone [10]. It will be interesting to examine
whether similar results are seen with gastric functions.
Post-prandial release of intestinal CCK and GLP-1 inhibit
gastric emptying and acid secretion [13,47]. These effects
are though to be meditated at least in part via intermedi-
ates released from the D-cell rather than by directly
inhibiting the acid-secreting parietal cell [48]. It was
believed that somatostatin was the sole intermediate but
the results of the current study suggest that paracrine reg-
ulation by amylin of parietal, ECL- and other endocrine
cells may have a role in the integrative responses to meals.
The amylin-induced inhibition of histamine released
from rat fundic mucosal segments in vitro was mediated
via increased somatostatin release [19] but using a selec-
tive somatostatin receptor antagonist Rossowski et al
Inhibitory effects of octreotide and carbachol on agonist- stimulated amylin (top) and somatostatin (bottom) release Figure 6
Inhibitory effects of octreotide and carbachol on agonist-
stimulated amylin (top) and somatostatin (bottom) release. 
D-cells were stimulated with either CCK 10 nM or epine-
phrine with isobutylmethylxanthine both 100 µM (EPI) in 
combination with octreotide 10 nM (OCT) or carbachol 100 
µM (CBH) for 2 hours. Results expressed as % of cell con-
tent of peptide released, mean ± SEM, * P < 0.05 vs. relevant 
agonist-stimulated release.BMC Physiology 2003, 3 http://www.biomedcentral.com/1472-6793/3/13
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showed in vivo in rats that a portion of the acid-inhibitory
actions of both amylin and the related peptide adrenom-
edullin were somatostatin-independent [49]. The specific
roles of amylin in gastric physiology require further eluci-
dation but these data suggest that locally released amylin
is directly capable of regulating mucosal functions.
The responses to epinephrine and carbachol suggest that
autonomic innervation can regulate the secretion of amy-
lin. The overall balance in vivo would then depend on the
relative input of the inhibitory muscarinic and stimula-
tory adrenergic systems, combined with circulating endo-
crine and local paracrine and possibly luminal factors.
Conclusion
This study describes the initial characterisation of the fac-
tors regulating gastric amylin release. We have demon-
strated that amylin release can be stimulated by receptor-
dependent stimulation of either of the Ca2+/PKC and ade-
nylate cyclase/cAMP pathways and that physiologically
relevant peptides and neural mediators can enhance amy-
lin release. This supports the hypothesis that amylin may
module gastric mucosal function. This study confirms that
short-term cultures of cells enriched by elutriation will
provide a model for exploring the pathophysiological
release of gastric amylin and provide a route of further
understanding the role of amylin in regulation of gastric
motor and secretory function.
Methods
Materials
Matrigel was obtained from Universal Biologicals (Lon-
don, UK), octreotide from Novartis (Surrey, UK) and
Ham's F12/Dulbecco's modified Eagle's culture medium
(50:50, v:v), glutamine, Hanks balanced salt solution and
foetal calf serum were purchased from Gibco (Paisley,
UK). Sulphated cholecystokinin-8 (CCK), human GLP-1
and all other reagents were obtained from Sigma (Poole,
UK).
Cell isolation and culture
Primary cultures of rabbit gastric fundic mucosal cells
enriched for D-cells were obtained as described previously
[39,48]. Briefly, rabbit fundic mucosa was subjected to
sequential EDTA and collagenase digestion. The resulting
cell suspension was enriched for D-cells by counterflow
elutatriation using a Beckman JE 5.0 standard rotor as pre-
viously described. The D-cell enriched fraction was resus-
pended in complete culture medium (Ham's F12/
Dulbecco's modified Eagle's culture medium (50:50, v:v),
containing 2 mM glutamine, 10 mM HEPES pH 7.4,
0.22% NaHCO3, 10% foetal calf serum, 1 mg/l hydrocor-
tisone, 8 mg/l insulin, 100 mg/l penicillin, 100 mg/l gen-
tamicin, 100 mg/l streptomycin) and cultured on
Matrigel-coated 24 well tissue culture plates [50] at a den-
sity of 1 × 106 cells/well for 40 hours in an atmosphere of
5% CO2, 95% air at 37°C.
Release Studies
Cultured cells were washed 3 times in release medium
(Earl's balanced salt solution containing 0.1% bovine
serum albumin, 10 mM HEPES pH 7.4) to remove dead
and non-adherent cells. A further 1 ml of release medium
was added containing test agonists and cells incubated for
2 hours at 37°C in an atmosphere of 5% CO2, 95% air.
After the release period, the conditioned media was
aspirated and centrifuged to remove non-adherent cells.
Total cellular content of peptide was extracted by boiling
in 1 ml in distilled water. Conditioned media and cell
extracts were stored at -70°C until assayed for peptide
content [30].
Peptide measurement
Somatostatin concentrations were assessed by radioim-
munoassay (RIA) with antiserum K2, as described previ-
ously [39]. Half-maximal inhibition of binding occurred
at 2 fmol / tube and the intra-assay and inter-assay varia-
tion were 7% and 8% percent respectively. Amylin con-
centrations were measured by direct ELISA (Penninsula
Laboratories, Belmont, CA, USA), according to the manu-
facturers instructions. The assay has a range of 0.04–2 ng
/ ml, and intra-assay and inter-assay variation of < 5% and
<14% respectively. The antibody used has 100% cross
reactivity with amylin and amylin-amide but < 1% cross
reactivity with CGRP and negligible reaction with other
biologically active peptides. All experimental samples
from a single animal preparation were assayed in the same
RIA or ELISA.
Statistical analysis
Peptide release during the 2-hour period was expressed as
the percentage of the total cell content (TCC) of that pep-
tide. Each experimental condition was tested in duplicate
and results from a single animal preparation were
regarded as N = 1. Results are expressed as the mean ± SEM
of 3–6 separate animal preparations. Each 24 well plate
always included control (basal) wells and positive stimu-
lants. Peptide release by stimulants was compared to the
basal release on the relevant 24 well plate. One-way anal-
ysis of variance and Student's paired t-test were used to
determine significance. A P value of < 0.05 was regarded
as significant.
List of abbreviations
CCK, cholecystokinin; ECL-, enterochromaffin-like; GLP-
1, glucagon-like peptide-1; IAPP, islet amylioid polypep-
tide; IBMX, isobutylmethylxanthine; PKC, protein kinase
C; PMA, phorbol-12-myristate-13-acetate, TCC, total cell
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